The present disclosure provides novel methods for treatment of patients with
autophagy diseases by administering a
prodrug of
dexibuprofen, such as but not limited to
dexibuprofen dimethylamino
ethyl ester (mDex) or a pharmaceutically acceptable salt thereof and compositions comprising the same.